Literature DB >> 11754109

Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I.

Orly N Elpeleg1, Avraham Shaag, Elizabeth Holme, Ghaleb Zughayar, Suzi Ronen, Drora Fisher, Haggit Hurvitz.   

Abstract

Thirteen Israeli patients with type I tyrosinemia were studied. To the best of our knowledge, this group represents all of the patients that were diagnosed in Israel during the years 1987-1997. Their age of onset was variable but all the patients suffered from liver disease at presentation. Six died at 3 to 36 months of age, whereas the remaining 7, in whom NTBC was started at 5 to 30 months, are alive and well at 4 to 11 years. Three mutations were identified: a mis-splicing IVS8-1G>C mutation in a large Moslem kindred, Pro261Leu mutation in all Jewish patients, and the IVS12+5G>A mutation, commonly found in French Canadian patients. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754109     DOI: 10.1002/humu.9001

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease.

Authors:  A Dursun; R K Ozgül; S Sivri; A Tokatlı; A Güzel; L Mesci; M Kılıç; D Aliefendioglu; F Ozçay; M Gündüz; T Coşkun
Journal:  JIMD Rep       Date:  2011-06-22

2.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

3.  The homogentisate pathway: a central catabolic pathway involved in the degradation of L-phenylalanine, L-tyrosine, and 3-hydroxyphenylacetate in Pseudomonas putida.

Authors:  Elsa Arias-Barrau; Elías R Olivera; José M Luengo; Cristina Fernández; Beatriz Galán; José L García; Eduardo Díaz; Baltasar Miñambres
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

4.  Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.

Authors:  María Luz Couce; Paula Sánchez-Pintos; Luís Aldámiz-Echevarría; Isidro Vitoria; Victor Navas; Elena Martín-Hernández; Camila García-Volpe; Guillem Pintos; Luis Peña-Quintana; Tomás Hernández; David Gil; Félix Sánchez-Valverde; María Bueno; Iria Roca; Encarna López-Ruzafa; Carmen Díaz-Fernández
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

5.  Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.

Authors:  Imad Dweikat; Nada Qawasmi; Aysha Najeeb; Mohammad Radwan
Journal:  Metabol Open       Date:  2021-01-28

6.  A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity.

Authors:  Kazuo Kawabata; Jun Kido; Takanobu Yoshida; Shirou Matsumoto; Kimitoshi Nakamura
Journal:  Mol Genet Metab Rep       Date:  2022-07-01

7.  Identification of Novel Mutations in FAH Gene and Prenatal Diagnosis of Tyrosinemia in Indian Family.

Authors:  Jayesh J Sheth; Chitra M Ankleshwaria; Rajeshwari Pawar; Frenny J Sheth
Journal:  Case Rep Genet       Date:  2012-10-30

8.  Expanded genetic screening panel for the Ashkenazi Jewish population.

Authors:  Brett Baskovich; Susan Hiraki; Kinnari Upadhyay; Philip Meyer; Shai Carmi; Nir Barzilai; Ariel Darvasi; Laurie Ozelius; Inga Peter; Judy H Cho; Gil Atzmon; Lorraine Clark; Jin Yu; Todd Lencz; Itsik Pe'er; Harry Ostrer; Carole Oddoux
Journal:  Genet Med       Date:  2015-09-03       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.